These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. Carraway JW; Park S; McCune SA; Holycross BJ; Radin MJ J Cardiovasc Pharmacol; 1999 Mar; 33(3):451-60. PubMed ID: 10069682 [TBL] [Abstract][Full Text] [Related]
3. Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Alonso-Galicia M; Brands MW; Zappe DH; Hall JE Hypertension; 1996 Dec; 28(6):1047-54. PubMed ID: 8952595 [TBL] [Abstract][Full Text] [Related]
4. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade. Leenen FH; Yuan B Hypertension; 2001 Mar; 37(3):981-4. PubMed ID: 11244027 [TBL] [Abstract][Full Text] [Related]
5. Treatment of obese female and male SHHF/Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: effects on body weight, fat distribution, insulin resistance and systolic pressure. Radin MJ; Chu YY; Hoepf TM; McCune SA Obes Res; 1993 Nov; 1(6):433-42. PubMed ID: 16350319 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men. Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658 [TBL] [Abstract][Full Text] [Related]
7. The peripheral renin-angiotensin system is not involved in the hypertension of sheep exposed to prenatal dexamethasone. Peers A; Campbell DJ; Wintour EM; Dodic M Clin Exp Pharmacol Physiol; 2001 Apr; 28(4):306-11. PubMed ID: 11251645 [TBL] [Abstract][Full Text] [Related]
8. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats. Pu Q; Larouche I; Schiffrin EL Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331 [TBL] [Abstract][Full Text] [Related]
9. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Culman J; von Heyer C; Piepenburg B; Rascher W; Unger T Eur J Pharmacol; 1999 Feb; 367(2-3):255-65. PubMed ID: 10079000 [TBL] [Abstract][Full Text] [Related]
10. Impact of the renin-angiotensin system on cerebral perfusion following subarachnoid haemorrhage in the rat. Fassot C; Lambert G; Elghozi JL; Lambert E J Physiol; 2001 Sep; 535(Pt 2):533-40. PubMed ID: 11533142 [TBL] [Abstract][Full Text] [Related]
11. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. Ruilope L J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models. Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170 [TBL] [Abstract][Full Text] [Related]
13. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans. Belz GG; Butzer R; Kober S; Mutschler E J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530 [TBL] [Abstract][Full Text] [Related]
15. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. McIntyre M; MacFadyen RJ; Meredith PA; Brouard R; Reid JL J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143 [TBL] [Abstract][Full Text] [Related]
16. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Toblli JE; Muñoz MC; Cao G; Mella J; Pereyra L; Mastai R Obesity (Silver Spring); 2008 Apr; 16(4):770-6. PubMed ID: 18239590 [TBL] [Abstract][Full Text] [Related]
17. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. von Vigier RO; Zberg PM; Teuffel O; Bianchetti MG Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237 [TBL] [Abstract][Full Text] [Related]